Valoctocogene Roxaparvovec: Clinical Trials

4 trials of Valoctocogene Roxaparvovec, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 3, Active not recruiting 1

Follow Valoctocogene Roxaparvovec: new trials by email Literature Review of Valoctocogene Roxaparvovec trials Research Report on Valoctocogene Roxaparvovec

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
Valoctocogene roxaparvovec - Hemophilia A
Phase 3Active not recruitingBioMarin Pharmaceutical62023-12-252026-03-19
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
valoctocogene roxaparvovec - Hemophilia A
Phase 3CompletedBioMarin Pharmaceutical222020-12-082025-10-08
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg
Valoctocogene Roxaparvovec - Hemophilia A
Phase 3CompletedBioMarin Pharmaceutical12018-03-142023-10-03
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)
valoctocogene roxaparvovec - Hemophilia A
Phase 3CompletedBioMarin Pharmaceutical1442017-12-192025-03-25

Conditions studied

Blood Coagulation Disorders (4)  ·  Blood Coagulation Disorders, Inherited (4)  ·  Coagulation Protein Disorders (4)  ·  Genetic Diseases, Inborn (4)  ·  Hematologic Diseases (4)  ·  Hemophilia A (4)  ·  Hemorrhagic Disorders (4)  ·  Hemostatic Disorders (4)

Sponsors

BioMarin Pharmaceutical (4)

Countries

United States (3)  ·  Australia (2)  ·  Brazil (2)  ·  Taiwan (2)  ·  Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  South Africa (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Results publications

PMID 32915950, PMID 35294811, PMID 35879931, PMID 36812433, PMID 38616241, PMID 39024543, PMID 40986187

NIH funding

2017 (2)